AI Article Synopsis
- Cancer-testis antigens are important markers for identifying malignant breast cancer based on their variable expression levels linked to different cancer stages.
- Researchers analyzed the expression of 16 specific cancer-testis antigen genes in breast tissue samples from 25 female patients with and without metastasis using the RT-qPCR method.
- Results showed distinct patterns of gene expression: metastatic cases exhibited higher levels of MAGEA2, MAGEB1, and XAGE3, while non-metastatic cases displayed increased GAGE3 and PRAME1 expression.
Article Abstract
Cancer-testis antigens, effective markers of tissue malignant transformation, are characterized by heterogonous transcription depending on the pathological features of breast cancer. We performed screening of transcription profile of cancer-testis antigens specific for breast tumor tissues in female patients with and without regional metastasis. The relative expression of 16 genes (MAGEA1, MAGEA2, MAGEA3, MAGEA4, MAGEB1, MAGEB2, GAGE1, GAGE3, GAGE4, MAGEC1, BAGE, XAGE3, NY-ESO1, SSX2, SYCP1, and PRAME1) was analyzed by RT-qPCR method in biopsy specimens of the mammary gland tissues obtained during surgery from 25 patients. Differential transcription activity of cancer-testis antigens genes was observed in patients with metastatic (enhanced expression of MAGEA2, MAGEB1, and XAGE3 genes) and non-metastatic (enhanced expression of GAGE3 and PRAME1 genes) breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-018-4175-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction the functional impacts of highly deleterious non-synonymous variants of gene.
Mol Biol Res Commun
January 2025
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- TSGA10 is a protein involved in spermatogenesis and associated with various cancers, where mutations can lead to infertility and abnormal expression in tumors.
- Research identifies the impact of specific non-synonymous SNPs (nsSNPs) on TSGA10's structure and function using multiple predictive in-silico tools before conducting expensive lab experiments.
- The study highlights 15 significantly damaging amino acid changes, particularly in regions linked to interactions with other proteins, suggesting these mutations can greatly affect TSGA10's role in infertility and cancer research.
A Rare Case of Scrotal Swelling: Prostate Cancer Metastasis Masquerading as a Complicated Hydrocele.
Cureus
November 2024
Department of Urology, Mersey and West Lancashire Teaching Hospitals NHS Trust, Liverpool, GBR.
Metastasis of prostate cancer to the testes is exceptionally rare. We report the case of a 67-year-old male with a 10-year history of high-risk prostate cancer, previously treated and currently in remission, who presented with left scrotal swelling. The swelling was clinically and radiologically diagnosed as a hydrocele and treated surgically.
View Article and Find Full Text PDFEvaluation of MAGE-A4 expression in breast cancer and its impact on prognosis.
Cancer Sci
December 2024
Department of Personalized Cancer Immunotherapy/Center for Comprehensive Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
Melanoma-associated antigen (MAGE)-A4, a cancer testis antigen, presents a promising target for chimeric antigen receptor T cell therapy in refractory solid tumors, including breast cancer (BC). However, the lack of highly specific Abs against MAGE-A4 is a major challenge for the development of MAGE-A4-targeted immunotherapies. This study aimed to validate the specificity of a novel MAGE-A4 Ab (E701U) and examine MAGE-A4 expression in clinical BC samples.
View Article and Find Full Text PDFDecoding NY-ESO-1 TCR T cells: transcriptomic insights reveal dual mechanisms of tumor targeting in a melanoma murine xenograft model.
Front Immunol
December 2024
Laboratory of molecular immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia.
The development of T cell receptor-engineered T cells (TCR-T) targeting intracellular antigens is a promising strategy for treating solid tumors; however, the mechanisms underlying their effectiveness remain poorly understood. In this study, we employed advanced techniques to investigate the functional state of T cells engineered with retroviral vectors to express a TCR specific for the NY-ESO-1 157-165 peptide in the HLA-A*02:01 context. Flow cytometry revealed a predominance of naïve T cells.
View Article and Find Full Text PDFHigh-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME.
Immunother Adv
November 2024
Immunocore Limited, Abingdon, Oxfordshire, United Kingdom.
Background: PRAME (eferentially expressed ntigen in lanoma) is a cancer-testis antigen expressed in several tumor indications, representing an attractive anticancer target. However, its intracellular location limits targeting by traditional methods. PRAME peptides are presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules, indicating that a T cell receptor (TCR)-based strategy that redirects T cells to kill PRAME tumors could be a novel immunotherapeutic option.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!